Mumbai: molanupiravirAntiviral drug that recently got emergency use approval for the treatment of mild to moderate COVID-19 in India, was launched on Monday for Rs 1,399 for a full five-day course, making it the cheapest antiviral coronavirus during the pandemic. Became one of the remedies.
More than a dozen companies, including Hetero Sun Pharma, Natco and Dr Reddy’s are in the process of launching the oral therapy developed by Merck and its partner Ridgeback Biotherapeutics at prices ranging between Rs 1,500 and Rs 2,500 for a complete treatment, sources told TOI. Globally, antiviral pill is seen as a potential gamechanger covid Remdesivir used so far is the form of treatment administered intravenously and in a hospital setting.
humanity pharma, which has tied up with BDR Pharmaceuticals. On Monday, a company official said that it introduced its antiviral Molulife (200 mg) in Delhi and some other parts of the country. In addition, Sun Pharma has priced the antiviral at around Rs 1,500 for the entire course, and is making its ‘molxvir’ available in markets where there are more cases, and gradually across India.
The recommended dose of molanupiravir is 800 mg twice a day for five days. Experts said that the cost of treatment will remain competitive and affordable for the patients in view of the stiff competition among the market players. Molnupiravir is also the first oral anti-Covid pill approved by the UK drug regulator, while the US Food and Drug Administration recently approved it for the treatment of mild to moderate COVID-19 in adults and for those who: are at a high level. Increased risk of serious illness, including hospitalization or death.
Following USFDA approval, the Drug Controller General of India permitted restricted use of molnupiravir to treat adult patients with SpO2 (93%), and who are at high risk of disease progression.
Earlier in June, MSD signed licensing agreements with five generic companies including Sun Pharma, Cipla, Torrent, Emcure and Dr Reddy’s to manufacture and supply Molnupiravir in India and in more than 100 low and middle income countries.
Watch Launched: India’s first COVID antiviral tablet at Rs 1,399
More than a dozen companies, including Hetero Sun Pharma, Natco and Dr Reddy’s are in the process of launching the oral therapy developed by Merck and its partner Ridgeback Biotherapeutics at prices ranging between Rs 1,500 and Rs 2,500 for a complete treatment, sources told TOI. Globally, antiviral pill is seen as a potential gamechanger covid Remdesivir used so far is the form of treatment administered intravenously and in a hospital setting.
humanity pharma, which has tied up with BDR Pharmaceuticals. On Monday, a company official said that it introduced its antiviral Molulife (200 mg) in Delhi and some other parts of the country. In addition, Sun Pharma has priced the antiviral at around Rs 1,500 for the entire course, and is making its ‘molxvir’ available in markets where there are more cases, and gradually across India.
The recommended dose of molanupiravir is 800 mg twice a day for five days. Experts said that the cost of treatment will remain competitive and affordable for the patients in view of the stiff competition among the market players. Molnupiravir is also the first oral anti-Covid pill approved by the UK drug regulator, while the US Food and Drug Administration recently approved it for the treatment of mild to moderate COVID-19 in adults and for those who: are at a high level. Increased risk of serious illness, including hospitalization or death.
Following USFDA approval, the Drug Controller General of India permitted restricted use of molnupiravir to treat adult patients with SpO2 (93%), and who are at high risk of disease progression.
Earlier in June, MSD signed licensing agreements with five generic companies including Sun Pharma, Cipla, Torrent, Emcure and Dr Reddy’s to manufacture and supply Molnupiravir in India and in more than 100 low and middle income countries.
Watch Launched: India’s first COVID antiviral tablet at Rs 1,399
,